- Home
- TVGN vs AARD Comparison
TVGN vs AARD Comparison
Compare TVGN & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TVGN
- AARD
- Stock Information
- Founded
- TVGN 2020
- AARD 2017
- Country
- TVGN United States
- AARD United States
- Employees
- TVGN N/A
- AARD N/A
- Industry
- TVGN Blank Checks
- AARD Biotechnology: Pharmaceutical Preparations
- Sector
- TVGN Finance
- AARD Health Care
- Exchange
- TVGN Nasdaq
- AARD Nasdaq
- Market Cap
- TVGN 179.0M
- AARD 186.3M
- IPO Year
- TVGN N/A
- AARD 2025
- Fundamental
- Price
- TVGN $0.82
- AARD $11.29
- Analyst Decision
- TVGN Strong Buy
- AARD Strong Buy
- Analyst Count
- TVGN 1
- AARD 5
- Target Price
- TVGN $10.00
- AARD $32.60
- AVG Volume (30 Days)
- TVGN 476.3K
- AARD 203.4K
- Earning Date
- TVGN 11-18-2025
- AARD 11-14-2025
- Dividend Yield
- TVGN N/A
- AARD N/A
- EPS Growth
- TVGN N/A
- AARD N/A
- EPS
- TVGN N/A
- AARD N/A
- Revenue
- TVGN N/A
- AARD N/A
- Revenue This Year
- TVGN N/A
- AARD N/A
- Revenue Next Year
- TVGN N/A
- AARD N/A
- P/E Ratio
- TVGN N/A
- AARD N/A
- Revenue Growth
- TVGN N/A
- AARD N/A
- 52 Week Low
- TVGN $0.26
- AARD $4.88
- 52 Week High
- TVGN $3.09
- AARD $19.58
- Technical
- Relative Strength Index (RSI)
- TVGN 31.08
- AARD N/A
- Support Level
- TVGN $0.86
- AARD N/A
- Resistance Level
- TVGN $0.87
- AARD N/A
- Average True Range (ATR)
- TVGN 0.05
- AARD 0.00
- MACD
- TVGN 0.00
- AARD 0.00
- Stochastic Oscillator
- TVGN 6.65
- AARD 0.00
About TVGN Tevogen Bio Holdings Inc. Common Stock
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.